New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics

On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...

Related Keywords

Marjoriee Zettler , ,Drug Administration ,Oncologic Drugs Advisory Committee ,Regor Pharmaceuticals Inc ,Drug Administration Expedited Development ,Us Government Accountability Office ,Oncology Center ,Drug Administration Accelerated Approval Of Malignant Hematology ,Regor Pharmaceuticals ,Project Confirm ,Reduce Risk ,Require Stronger Evidence Of Safety And ,Drug Omnibus Reform Act ,Consolidated Appropriations Act ,Mantle Cell Lymphoma ,Marginal Zone Lymphoma ,Participants With ,Refractory Mantle Cell Lymphoma ,Tyrosine Kinase Inhibitor ,Subjects With ,Refractory Marginal Zone ,Tyrosine Kinase Inhibitor Ibrutinib Given ,Combination With Bendamustine ,Patients With Newly Diagnosed Mantle Cell ,Untreated Mantle Cell ,Combination With Either Bendamustine ,Expedited Programs ,Serious Conditions ,Preview Programs ,Nonorphan Novel Drugs Approved From ,Bend Points ,Patient Reported Outcomes ,Novel Oncology Drugs Approved Between ,Year Experience ,Drug Administration Accelerated Approval ,Malignant Hematology ,Oncology Drugs ,Many Applications ,Postapproval Oversight Need Improvement ,Appropriations Act ,Clinical Trial Considerations ,Support Accelerated Approval ,Clinical Oncology ,